Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Dapagliflozin
81%
Patient
81%
Glucose
77%
Therapeutic Procedure
59%
Cells
57%
Adipocyte
55%
Plasma
46%
Insulin
43%
Gluconeogenesis
42%
Insulin Resistance
39%
Adipose Tissue
38%
Placebo
38%
Inpatient
37%
Obesity
35%
Insulin Sensitivity
34%
Combination Therapy
33%
Adiponectin
31%
Leptin
29%
Insulin Release
28%
Glucagon-Like Peptide-1 Agonist
28%
Patient with Type 2 Diabetes
24%
Glucosuria
24%
Exenatide
21%
Pioglitazone
19%
Heart
19%
Chronic Kidney Disease
19%
Cell Function
19%
Cardiovascular System
19%
Hyperglycemia
19%
Glucose Uptake
18%
Glucagon
18%
Glycemic Control
17%
Paget's Disease
16%
Diabetes
16%
Lipid Diet
16%
Type 2 Diabetes
16%
Cardiovascular Disease
15%
Glucose Tolerance
15%
Osteoclast
15%
Oral Glucose Tolerance Test
14%
White Adipose Tissue
13%
Regulatory Mechanism
13%
Heart Function
13%
Kidney
12%
Hypercalcaemia
12%
Serositis
12%
Antidiabetic Agent
12%
Body Weight
11%
Gene
11%
Cotransporter
11%
Weight Loss
11%
Bone
11%
Development
11%
Mineralocorticoid Antagonist
11%
Fat
10%
Hypoglycemia
10%
Health Outcomes
10%
Diabetes Mellitus
10%
Male
10%
Metabolism
10%
Chemotherapeutic Agent
9%
Drug
9%
Empagliflozin
9%
Creatine Phosphate
9%
Pheochromocytoma
9%
Iron
9%
Cannabinoid 1 Receptor
9%
Vascular Disease
9%
Osteoclast Differentiation Factor
9%
Hepatocyte Nuclear Factor 4
9%
Peroxisome Proliferator Activated Receptor
9%
Gonadorelin Agonist
9%
Calcium Excretion
9%
Primary Hyperparathyroidism
9%
Finerenone
9%
Patient with Type 1 Diabetes
9%
Semaglutide
9%
Human Study
9%
Physical Activity
9%
Musculoskeletal Health
9%
Meta-Analysis
9%
Placebo
9%
Absorptiometry
9%
Infusion
9%
Congestive Heart Failure
9%
Ketone
9%
Case Report
9%
Evaluation Study
9%
Adenosine Triphosphate
8%
Observation
8%
Association
8%
C-Peptide
8%
Adverse Event
8%
Diseases
8%
Chronic Myelogenous Leukemia
8%
Acipimox
8%
Hemoglobin A1c
8%
Connexin 43
8%
Hypophysis Apoplexy
8%
Biochemistry, Genetics and Molecular Biology
Mouse
54%
Adipocyte
47%
Glucose
37%
Insulin Release
20%
Fat
17%
Knockout Mouse
16%
Dapagliflozin
15%
Gluconeogenesis
14%
Insulin Resistance
13%
Adiponectin
12%
Free Fatty Acids
12%
Peptide
11%
Hyaluronan
9%
Galactose
9%
Pyruvate Kinase
9%
Iron
9%
Dimethyl Sulfoxide
9%
Lipid Droplet
9%
Bile Acid Synthesis
9%
Bile Acid
9%
Syntaxin
9%
Hepatocyte Nuclear Factor 4
9%
Calcium Excretion
9%
Calcium Urine Level
9%
Ossification
9%
Human Study
9%
Physical Activity
9%
Insulin
9%
Nested Gene
9%
Metabolic Pathway
8%
Glucose Blood Level
8%
Excretion
8%
Glucose Metabolism
7%
Electric Potential
7%
Lysozyme
7%
Lipolysis
6%
Cotransporter
6%
Osteolysis
6%
Mouse Model
6%
Transmembrane Protein
6%
Glucose Homeostasis
5%
Phenotype
5%
Lipid
5%
Pressure
5%
Insulin Sensitivity
5%
Drive
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
31%
Leptin
29%
Mouse
21%
Semaglutide
19%
Pioglitazone
19%
Adiponectin
18%
Dapagliflozin
17%
Obesity
15%
Insulin Resistance
14%
Glucose
11%
Insulin
10%
Vascular Disease
9%
Liraglutide
9%
Bile Acid
9%
Dimethyl Sulfoxide
9%
Liver Injury
9%
Prasterone
9%
Semaglutide
9%
Linagliptin
9%
Empagliflozin
9%
Hepatocyte Nuclear Factor 4
9%
Nonalcoholic Fatty Liver
9%
Peroxisome Proliferator Activated Receptor
9%
Muscone
9%
Primary Hyperparathyroidism
9%
Hyperleptinemia
9%
Placebo
9%
Glucagon Like Peptide 1 Receptor Agonist
9%
Glitazone Derivative
8%
Drug
7%
Antidiabetic Agent
7%
Adverse Event
7%
Diseases
6%
Placebo
6%
Diethylstilbestrol
6%
Osteoporosis
5%
Leptin Deficiency
5%
Estrogen
5%
Luciferase
5%
Hyperglycemia
5%
Saxagliptin
5%